Critical pathophysiological roles of a potential therapeutic target RHBDL2 in triple negative breast cancer

被引：0
|
作者：
Okumura, Kazumasa [1 ,2 ,3 ]
Matsushita, Yosuke [1 ]
Komatsu, Masato [1 ]
Kimura, Ryuichiro [1 ]
Yoshimaru, Tetsuro [1 ]
Ono, Masaya [4 ]
Miyoshi, Yasuo [5 ]
Honda, Junko [6 ]
Sasa, Mitsunori [7 ]
Tangoku, Akira [8 ]
Katagiri, Toyomasa [1 ]
机构：
[1] Tokushima Univ, Inst Genome Res, Div Genome Med, Tokushima, Japan
[2] Tokushima Univ, Dept Thorac Endocrine Surg, Tokushima, Japan
[3] Higashi Tokushima Med Ctr, Dept Surg, Tokushima, Japan
[4] Natl Canc, Div Chemother Clin Res, Tokyo, Japan
[5] Hyogo Coll Med, Dept Surg, Nishinomiya, Hyogo, Japan
[6] Natl Hosp Org Higashitokushima Med Ctr, Dept Surg, Itano, Tokushima, Japan
[7] Tokushima Breast Care Clin, Dept Surg, Tokushima, Japan
[8] Tokushima Univ, Dept Thorac Endocrine Surg, Tokushima, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2279
引用
收藏
页码：960 / 960
页数：1
相关论文
共 50 条
  • [1] Critical roles of RHBDL2 overexpression in carcinogensis of triple negative breast cancer
    Okumura, Kazumasa
    Matsushita, Yosuke
    Komatsu, Masato
    Kimura, Ryuichiro
    Yoshimaru, Tetsuro
    Ono, Masaya
    Miyoshi, Yasuo
    Honda, Junko
    Sasa, Mitsunori
    Tangoku, Akira
    Katagiri, Toyomasa
    CANCER SCIENCE, 2018, 109 : 525 - 525
  • [2] RHBDL2 play crucial roles for chemoresistance via regulating glutaminolysis in triple negative breast cancer
    Matsushita, Yosuke
    Okumura, Kazumasa
    Komatsu, Masato
    Yoshimaru, Tetsuro
    Ono, Masaya
    Miyoshi, Yasuo
    Sasa, Mitsunori
    Katagiri, Toyomasa
    CANCER SCIENCE, 2023, 114 : 1952 - 1952
  • [3] RHBDL2-ASCT2 axis have critical roles for modulating glutaminolysis in triple negative breast cancer
    Matsushita, Yosuke
    Okumura, Kazumasa
    Komatsu, Masato
    Yoshimaru, Tetsuro
    Ono, Masaya
    Miyoshi, Yasuo
    Sasa, Mitsunori
    Katagiri, Toyomasa
    CANCER SCIENCE, 2024, 115 : 1602 - 1602
  • [4] Potential therapeutic target for triple-negative breast cancer
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2012, 13 (08): : E330 - E330
  • [5] Triple-negative breast cancer: investigating potential molecular therapeutic target
    Papa, Anselmo
    Caruso, Davide
    Tomao, Silverio
    Rossi, Luigi
    Zaccarelli, Eleonora
    Tomao, Federica
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (01) : 55 - 75
  • [6] CXCL16 as a potential therapeutic target of triple-negative breast cancer
    Cho, Sun Wook
    Jang, Mi Gyeong
    Sun, Hyun Jin
    Lee, Han Sai
    Song, Young Shin
    Kim, Seong Keun
    CANCER RESEARCH, 2022, 82 (04)
  • [7] LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer
    Maubant, S.
    Maire, V.
    Tesson, B.
    Gentien, D.
    Marty-Prouvose, B.
    Cruzalegui, F.
    Depil, S.
    Tucker, G. C.
    Roman-Roman, S.
    Dubois, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 161 - 162
  • [8] LncRNA MALAT1 as a potential therapeutic target in triple negative breast cancer
    Adewunmi, Oluwatoyosi
    Rosen, Jeffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [9] Hepatic Leukemia Factor (HLF), a potential therapeutic target in triple negative breast cancer
    Bouakka, Ibrahim
    Tran-Dien, Alicia
    Sirerol, Marine
    Silvin, Aymeric
    Andre, Fabrice
    Rocca, Anna
    CANCER RESEARCH, 2023, 83 (05)
  • [10] mGluR1 as a potential therapeutic target in the treatment of triple negative breast cancer
    Speyer, Cecilia L.
    Smith, Jennifer S.
    Banda, Malathi
    Mekani, Tassia
    Gorski, David H.
    CANCER RESEARCH, 2011, 71
12345